LONGEVERON INC-A (LGVN)
US54303L2034 - Common Stock
LONGEVERON INC-A
NASDAQ:LGVN (10/21/2024, 8:25:37 PM)
After market: 2.06 -0.03 (-1.44%)2.09
-0.1 (-4.57%)
Company Profile
Longeveron Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Miami, Florida and currently employs 23 full-time employees. The company went IPO on 2021-02-12. Longeveron Inc. is a clinical-stage biotechnology company. The firm is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The firm's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The firm is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The firm has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
Company Info
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136
P: 13053027158
CEO: Geoff Green
Employees: 24
Website: https://www.longeveron.com/
LGVN News
8 days ago - LongeveronLongeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24)....
13 days ago - LongeveronLongeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual MeetingLongeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg....
15 days ago - LongeveronLongeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy DayWa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct...
20 days ago - LongeveronLongeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceLongeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s....
25 days ago - InvezzBioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the MesaLongeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. The company today announced that it will attend the Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine. The conference is scheduled for October 7-9, 2024, in Phoenix, Arizona. […]
26 days ago - LongeveronLongeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the MesaLongeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services....
LGVN Twits
Here you can normally see the latest stock twits on LGVN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
